Cody Coblentz
Overview
Explore the profile of Cody Coblentz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
865
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development
Carratt S, Kong G, Coblentz C, Schonrock Z, Maloney L, Weeder B, et al.
Leukemia
. 2023 Mar;
37(5):1141-1146.
PMID: 36894620
No abstract available.
2.
Braun T, Estabrook J, Schonrock Z, Curtiss B, Darmusey L, Macaraeg J, et al.
Leukemia
. 2022 Dec;
37(2):478-487.
PMID: 36526735
Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis....
3.
Bottomly D, Long N, Schultz A, Kurtz S, Tognon C, Johnson K, et al.
Cancer Cell
. 2022 Jul;
40(8):850-864.e9.
PMID: 35868306
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and clinical annotations for a large...
4.
Carratt S, Braun T, Coblentz C, Schonrock Z, Callahan R, Curtiss B, et al.
Leukemia
. 2022 Jul;
36(8):2149.
PMID: 35794242
No abstract available.
5.
Braun T, Okhovat M, Coblentz C, Carratt S, Foley A, Schonrock Z, et al.
Nat Commun
. 2022 Jun;
13(1):3471.
PMID: 35710794
No abstract available.
6.
Carratt S, Braun T, Coblentz C, Schonrock Z, Callahan R, Curtiss B, et al.
Leukemia
. 2021 May;
35(12):3594-3599.
PMID: 34002029
Mutations in SET-binding protein 1 (SETBP1) are associated with poor outcomes in myeloid leukemias. In the Ras-driven leukemia, juvenile myelomonocytic leukemia, SETBP1 mutations are enriched in relapsed disease. While some...
7.
Braun T, Coblentz C, Curtiss B, Coleman D, Schonrock Z, Carratt S, et al.
Proc Natl Acad Sci U S A
. 2020 May;
117(24):13670-13679.
PMID: 32471953
Acute myeloid leukemia (AML) is a deadly hematologic malignancy with poor prognosis, particularly in the elderly. Even among individuals with favorable-risk disease, approximately half will relapse with conventional therapy. In...
8.
Braun T, Okhovat M, Coblentz C, Carratt S, Foley A, Schonrock Z, et al.
Nat Commun
. 2019 Dec;
10(1):5455.
PMID: 31784538
Acute Myeloid Leukemia (AML) develops due to the acquisition of mutations from multiple functional classes. Here, we demonstrate that activating mutations in the granulocyte colony stimulating factor receptor (CSF3R), cooperate...
9.
Tyner J, Tognon C, Bottomly D, Wilmot B, Kurtz S, Savage S, et al.
Nature
. 2018 Oct;
562(7728):526-531.
PMID: 30333627
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic...
10.
Zhang H, Coblentz C, Watanabe-Smith K, Means S, Means J, Maxson J, et al.
J Biol Chem
. 2018 Mar;
293(19):7387-7396.
PMID: 29572350
Granulocyte colony-stimulating factor (G-CSF or CSF3) and its receptor CSF3R regulate granulopoiesis, neutrophil function, and hematopoietic stem cell mobilization. Recent studies have uncovered an oncogenic role of mutations in the...